Qiao C. Li
Chinese Academy Of Medical Sciences And Peking Union Medical College
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 119 publications
Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer: A Single-Center Pooled Analysis.
Journal: Thoracic cancer
Published: April 12, 2026
Sleep Disturbance, Treatment-Related Adverse Events, and Psychological Distress in Breast Cancer Patients: A Prospective Cohort Study.
Journal: Patient preference and adherence
Published: March 11, 2026
Mitoxantrone hydrochloride liposome (Lipo-MIT) combined with capecitabine in HER2-negative advanced breast cancer: a dose-escalation, phase I study.
Journal: BMC medicine
Published: February 08, 2026
Efficacy, Safety, and Prognostic Factors of Dalpiciclib Combined with Endocrine Therapy After Progression on CDK4/6 Inhibitors in Patients with HR+/HER2- Advanced Breast Cancer: A Retrospective Study.
Journal: Breast cancer (Dove Medical Press)
Published: December 18, 2025
Prognostic value of Ki-67 index in malignant phyllodes tumor of the breast: a multi-center real-world study.
Journal: Breast cancer research : BCR
Published: October 27, 2025
Efficacy of neoadjuvant endocrine therapy with CDK4/6 inhibitors in locally advanced breast cancer.
Journal: The oncologist
Published: September 05, 2025
Trastuzumab and pertuzumab plus carboplatin-based neoadjuvant therapy for HER2-positive breast cancer: a prospective cohort study with integrated genomic and transcriptomic biomarker analysis.
Journal: Therapeutic advances in medical oncology
Published: August 12, 2025
Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world study.
Journal: Therapeutic advances in medical oncology
Published: July 22, 2025
Pathologic complete response after neoadjuvant chemotherapy for HER-2 negative breast cancer with HRR mutation.
Journal: Future oncology (London, England)
Published: July 21, 2025
Pathological complete response and survival outcomes in single hormone receptor-positive/HER2-negative breast cancer after neoadjuvant chemotherapy and its intrinsic biological features and immune landscape.
Journal: Breast cancer research and treatment
Published: July 11, 2025
Associations between dynamic hematological indicators and outcomes in HR-positive, HER2-negative metastatic breast cancer treated with bireociclib or placebo plus fulvestrant: Findings from the BRIGHT-2 trial.
Journal: Breast (Edinburgh, Scotland)
Published: June 27, 2025
Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens.
Journal: Cancer innovation
Published: February 25, 2025
Last Updated: 09/26/2026